Skip to content
PubMed This is a summary of 11 peer-reviewed journal articles Updated
Infectious Disease

Do Corticosteroid Medications Cause CMV Reactivation?

At a Glance

High-dose or prolonged corticosteroids can allow dormant cytomegalovirus (CMV) to become active, especially in people whose immune systems are weakened by transplant, cancer treatment, or other immune-suppressing medicines. Testing is based on individual risk.

High-dose or prolonged systemic corticosteroid treatments (such as prednisone or dexamethasone) can increase your risk of a cytomegalovirus (CMV) reactivation. However, steroids do not predictably cause a flare-up in everyone. The risk depends heavily on your underlying disease, your specific steroid dose, prior CMV exposure, and whether your immune system is already severely suppressed by other treatments or conditions [1].

How Steroids Affect Your Immune Defenses

Most adults have been exposed to CMV at some point in their lives. After the initial infection, the virus never leaves the body; it goes into a dormant (sleeping) state. Your immune system has specialized “guards”—specifically white blood cells known as T-cells and Natural Killer (NK) cells—that work around the clock to keep the virus suppressed [2][3].

Corticosteroids are powerful anti-inflammatory drugs that treat conditions by intentionally turning down your immune response. When you take high doses of steroids, your T-cells and NK cells can become temporarily impaired [4]. Without these cells functioning at full strength, they may struggle to keep CMV in check, creating an opportunity for the virus to wake up and begin multiplying [4].

Who Is Most at Risk?

The risk of CMV reactivation is highest for patients who already have severely weakened immune systems. This includes individuals undergoing stem cell or solid organ transplants, receiving CAR T-cell therapy for cancer, or taking heavy immunosuppression for severe autoimmune diseases [1][5].

In these complex medical situations, steroids are rarely used alone. Risk is shaped by a combination of factors, including:

  • Prior CMV exposure (your CMV IgG status, and your donor’s status if you had a transplant) [6]
  • Conditioning chemotherapy or graft-versus-host disease (GVHD) [7]
  • The use of other strong immunosuppressive drugs [6]

Because these therapies are combined, it can be hard to pinpoint steroids as the single cause of a flare-up, though high doses of glucocorticoids are recognized as a major contributing risk factor [5]. For instance, in one specific high-risk group (patients receiving BCMA-targeted CAR T-cell therapy), using steroids for more than three days was associated with a significantly higher risk of reactivation [8]. However, this does not mean a brief steroid course poses the same risk for someone who is not severely immunocompromised.

Reactivation vs. CMV Disease

It is important to distinguish between the virus simply waking up and the virus causing illness:

  • CMV Reactivation: This means the virus is actively multiplying in your body. It is usually detected by a blood test (called a quantitative CMV PCR) that measures viral DNA. Reactivation often causes no physical symptoms at all [9].
  • CMV Disease: This occurs when the virus causes actual physical symptoms or damages tissues (such as the lungs, colon, or eyes). While worse health outcomes are often linked to a high or persistent viral burden in the blood, tissue-invasive disease can sometimes occur even if blood viral levels are low [10].

Urgent Symptoms to Watch For

If you are highly immunosuppressed and taking steroids, contact your medical team promptly if you experience new or worsening symptoms, such as:

  • New eye floaters, blurred vision, or loss of vision (which requires urgent evaluation for CMV eye disease)
  • Unexplained persistent fever or severe fatigue
  • Worsening diarrhea, abdominal pain, or blood in your stool
  • Shortness of breath or trouble breathing
  • Severe weakness, confusion, or difficulty swallowing

Monitoring and Treatment

Not everyone taking steroids needs to be tested for CMV. Routine CMV PCR monitoring is common in highly immunosuppressed settings (like after a stem cell transplant), but it is not automatically required for every person taking steroids for an autoimmune condition.

If your immune system starts to recover—often as your doctor gradually reduces your steroid dose—your T-cells may regain their strength and help bring the virus back under control [11]. However, immune recovery does not guarantee spontaneous clearance, and many high-risk patients still require antiviral medications or close specialist surveillance.

Important safety warning: Never stop taking your prescribed steroids abruptly without consulting your doctor. Stopping suddenly can be dangerous. Your medical team must carefully balance treating your underlying condition while managing your CMV risk.

Common questions in this guide

Can high-dose or long-term steroids reactivate CMV?
Yes. High-dose or prolonged systemic corticosteroids can weaken the immune cells that keep dormant CMV under control. The risk is highest when the immune system is already severely suppressed, and a steroid course does not cause reactivation in everyone.
How is CMV reactivation different from CMV disease?
CMV reactivation means the virus is multiplying again, often without symptoms, and is usually found with a quantitative CMV PCR blood test. CMV disease means the virus is causing symptoms or tissue damage, such as problems involving the eyes, lungs, or colon. Blood viral levels do not always reflect tissue disease.
Do all people taking corticosteroids need CMV PCR monitoring?
No. Routine CMV PCR monitoring is most common after stem cell or solid organ transplantation, CAR T-cell therapy, or other situations with severe immune suppression. Your medical team should decide based on your steroid dose, treatment duration, prior CMV exposure, underlying condition, and other immune-suppressing medicines.
What symptoms of CMV should I report urgently while taking steroids?
If you are highly immunosuppressed, promptly report new vision changes or eye floaters, persistent fever, severe fatigue, worsening diarrhea, abdominal pain or blood in the stool, shortness of breath, confusion, or difficulty swallowing. Vision loss, severe breathing trouble, or rapidly worsening symptoms may require emergency evaluation. Ask your care team which symptoms should trigger an immediate call for your situation.
Should I stop my steroid if I am worried about CMV reactivation?
No, do not stop prescribed corticosteroids abruptly unless your clinician tells you to. Sudden withdrawal can be dangerous, and your care team may need to balance steroid treatment with CMV testing, a gradual dose reduction, or antiviral medication.
What happens if my CMV PCR level starts to rise?
A rising CMV PCR result does not by itself determine the treatment plan. Your clinicians will consider the trend, symptoms, immune status, transplant or cancer therapy history, and risk of tissue disease when deciding whether to start an antiviral. Do not wait to report new symptoms while results are being followed.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Cytomegalovirus Infection.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given my specific medical history and steroid dose, do I need routine CMV PCR blood tests to monitor for a reactivation?
  2. 2.If my CMV viral load begins to rise, at what trend or clinical threshold would we consider starting an antiviral medication?
  3. 3.Are there specific urgent symptoms—such as vision changes or severe diarrhea—that should prompt me to contact the clinic immediately or go to the emergency room?
  4. 4.How do my prior CMV exposure status and my other immunosuppressive medications affect my overall risk?
  5. 5.What side effects or drug interactions should I watch for if an antiviral is prescribed?

References

References (11)
  1. 1

    Incidence and outcomes of cytomegalovirus reactivation after chimeric antigen receptor T-cell therapy.

    Lin RY, Anderson AD, Natori Y, et al.

    Blood advances 2024; (8(14)):3813-3822 doi:10.1182/bloodadvances.2024012922.

    PMID: 38838226
  2. 2

    Functional specific-T-cell expansion after first cytomegalovirus reactivation predicts viremia control in allogeneic hematopoietic stem cell transplant recipients.

    Ciáurriz M, Beloki L, Zabalza A, et al.

    Transplant infectious disease : an official journal of the Transplantation Society 2017; (19(6)) doi:10.1111/tid.12778.

    PMID: 28921749
  3. 3

    Reconstitution of Human Cytomegalovirus-Specific CD4+ T Cells is Critical for Control of Virus Reactivation in Hematopoietic Stem Cell Transplant Recipients but Does Not Prevent Organ Infection.

    Gabanti E, Lilleri D, Ripamonti F, et al.

    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2015; (21(12)):2192-2202 doi:10.1016/j.bbmt.2015.08.002.

    PMID: 26260678
  4. 4

    Impaired T cells and "memory-like" NK-cell reconstitution is linked to late-onset HCMV reactivation after letermovir cessation.

    Lauruschkat CD, Muchsin I, Rein AF, et al.

    Blood advances 2024; (8(11)):2967-2979 doi:10.1182/bloodadvances.2023012008.

    PMID: 38315873
  5. 5

    [Reactivation of cytomegalovirus and its influencing factors in patients with B-lymphocyte malignancy after CAR-T cell therapy].

    Wang ZH, Li LH, Xue SL, et al.

    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2024; (45(11)):1005-1009 doi:10.3760/cma.j.cn121090-20240703-00249.

    PMID: 39746693
  6. 6

    Risk Factors for Cytomegalovirus Infection After Allogeneic Hematopoietic Cell Transplantation in Malignancies: Proposal for Classification.

    Dziedzic M, Sadowska-Krawczenko I, Styczynski J

    Anticancer research 2017; (37(12)):6551-6556 doi:10.21873/anticanres.12111.

    PMID: 29187429
  7. 7

    The association of conditioning regimen with cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation.

    Mardani M, Abolghasemi S, Shabani S, et al.

    Iranian journal of microbiology 2020; (12(6)):636-643 doi:10.18502/ijm.v12i6.5040.

    PMID: 33613920
  8. 8

    Cytomegalovirus (CMV) Reactivation and CMV-Specific Cell-Mediated Immunity After Chimeric Antigen Receptor T-Cell Therapy.

    Kampouri E, Ibrahimi SS, Xie H, et al.

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2024; (78(4)):1022-1032 doi:10.1093/cid/ciad708.

    PMID: 37975819
  9. 9

    Murine cytomegalovirus dissemination but not reactivation in donor-positive/recipient-negative allogeneic kidney transplantation can be effectively prevented by transplant immune tolerance.

    Dangi A, Yu S, Lee FT, et al.

    Kidney international 2020; (98(1)):147-158 doi:10.1016/j.kint.2020.01.034.

    PMID: 32471635
  10. 10

    Cytomegalovirus Reactivation in Critically Ill Patients With Acute Necrotizing Pancreatitis.

    Singh U, Gurjar M, Garg A, et al.

    Open forum infectious diseases 2025; (12(8)):ofaf438 doi:10.1093/ofid/ofaf438.

    PMID: 40838259
  11. 11

    Cytomegalovirus Infections in Hematopoietic Stem Cell Transplant: Moving Beyond Molecular Diagnostics to Immunodiagnostics.

    Gupta C, Mundan NG, Das S, et al.

    Diagnostics (Basel, Switzerland) 2024; (14(22)) doi:10.3390/diagnostics14222523.

    PMID: 39594189

This page is for informational purposes only and does not constitute medical advice. Your treating team should decide whether you need CMV testing, a steroid dose change, or antiviral treatment.